The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Translating the neuroscience of alcoholism into clinical treatments: From blocking the buzz to curing the blues
Open accessAbstract
Understanding the pathophysiology of addictive disorders is critical for development of new treatments. A major focus of addiction research has for a long time been on systems that mediate acute positively reinforcing effects of addictive drugs, most prominently the mesolimbic dopaminergic (DA) system and its connections. This research line has been successful in shedding light on the physiology of both natural and drug reward, but has not led to therapeutic breakthroughs. The role of classical reward systems is perhaps least clear in alcohol addiction. Here, recent work is summarized that points to some clinically important conclusions. First, important pharmacogenetic differences exist with regard to positively reinforcing effects of alcohol and the ability of this drug to activate classical reward pathways. This offers an opportunity for personalized treatment approaches in alcoholism. Second, brain stress and fear systems become pathologically activated in later stages of alcoholism and their activation is a major influence in escalation of alcohol intake, sensitization of stress responses, and susceptibility to relapse. These findings offer a new category of treatment mechanisms. Corticotropin-releasing hormone (CRH) signaling through CRH1 receptors is a major candidate target in this category, but recent data indicate that antagonists for substance P (SP) neurokinin 1 (NK1) receptors may have a similar potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although initial drug intake is associated with positive reinforcement and impulsive actions, chronic drug use is characterized by compulsive drug-taking behavior despite negative consequences.4, 5, 6”
From Behavioral and neuroimaging evidence for overreliance on habit learning in alcohol-dependent patients (2013) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“To date, treatment programs for AD have mainly tried to reduce the positive reinforcing properties of drugs (‘blocking the buzz' for example, with the opioid antagonist naltrexone) or to reduce the negative reinforcing aspects of chronic alcohol use represented by relief craving (‘curing the blues' for example, with acamprosate).5”
From Behavioral and neuroimaging evidence for overreliance on habit learning in alcohol-dependent patients (2013) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kirschbaum, C., Pirke, K.-M., & Hellhammer, D. H. (2008) · Neuropsychobiology · doi:10.1159/000119004 · Cited by 6,093
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Predictive reward signal of dopamine neurons
Schultz, W. (1998) · Journal of Neurophysiology · doi:10.1152/jn.1998.80.1.1 · Cited by 4,564
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
Vale, W., Spiess, J., RIVIER, C. L., & Rivier, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904
Selected major risk factors and global and regional burden of disease
Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S., & Murray, C. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11403-6 · Cited by 3,594
Bardo, M. T., & Hammer, R. P. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90226-e · Cited by 3,229
Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908
International Affective Picture System (IAPS) : Technical Manual and Affective Ratings
Lang, P. J. (1995) · Medical Entomology and Zoology · Cited by 2,870
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622 · cited 1×
“…of addictive drugs may play an important role in early stages of addiction, but that addiction is a chronic relapsing disorder, ultimately maintained by pathology of brain function that arises over time, and only in a minority of subjects that initially engage in drug use (McLellan et al., 2000).”
Background
Research works printed but not linked: 1
- Thorsell A Schank JR Singley E Hunt SP Heilig M 2009 The neurokinin-1 receptor is required for alcohol reward and escalation of alcohol intake In press PNAS
Cited by
Sorted by citations
Opiate versus psychostimulant addiction: the differences do matter
Badiani, A., Belin, D., Epstein, D. H., Calu, D. J., & Shaham, Y. (2011) · Nature reviews. Neuroscience · doi:10.1038/nrn3104 · Cited by 491
Addictions neuroclinical assessment: a neuroscience-based framework for addictive disorders
Kwako, L. E., Momenan, R., Litten, R. Z., Koob, G. F., & Goldman, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.024 · Cited by 395
Sjoerds, Z., de Wit, S., van den Brink, W., Robbins, T. W., Beekman, A. T. F., Penninx, B. W. J. H., & Veltman, D. J. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.107 · Cited by 312
Breese, G. R., Sinha, R., & Heilig, M. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.09.007 · Cited by 274
Self-citationCorticotropin releasing factor: A key role in the neurobiology of addiction
Zorrilla, E. P., Logrip, M. L., & Koob, G. F. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.01.001 · Cited by 267
Metadata
- Authors
- Heilig, M., Thorsell, A., Sommer, W. H., Hansson, A. C., Ramchandani, V. A., George, D. T., Hommer, D., & Barr, C. S.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Heilig, Markus
- ORCID
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 35
- Issue
- 2
- Pages
- 334-344
- ISSN
- 0149-7634 (ISSN-L)
- PMC
- PMC2891917
- OpenAlex
- W2010733076
- Cited by
- 117
- References
- 144
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 2 · 2019: 5 · 2018: 3 · 2017: 11 · 2016: 9 · 2015: 11 · 2014: 13 · 2013: 9 · 2012: 15
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuroscience & Biobehavioral Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (ZIAAA000487)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- alcoholism, mesolimbic dopamine system, drug reward, pharmacogenetics, personalized treatment, relapse, corticotropin-releasing factor, substance P, NK1 receptor antagonists
- MeSH terms
- CRF Receptor, Type 1, Ethanol, Alcoholism, Animals, Brain, Corticotropin-Releasing Hormone, Humans, Models, Biological, Substance P, Drug Delivery Systems, Receptors, Corticotropin-Releasing Hormone, Translational Research, Biomedical, Neurokinin-1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
